We partnered with Seattle Children’s Hospital and the University of Washington to conduct our studies. The studies concluded that our API is a potent and non-toxic ingredient against the most problematic pathogens in the CF community. Given these preclinical results, EVQ-218 is a unique and promising therapy for cystic fibrosis beyond Pseudomonas.
In October 2021 we received an additional grant from CFF to continue our testing. This award will support the preclinical testing of our lead asset for the treatment of multi-drug resistant pulmonary bacterial infections in patients diagnosed with cystic fibrosis.